Oncimmune
Operates as a cancer detection company. The Company focuses on the development of autoantibody assay technologies that allow cancer detection earlier than other methods.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| GBP | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 631 % | 4 % | (70 %) | 138 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (1815 %) | (108 %) | (185 %) | (385 %) | (110 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (1662 %) | (124 %) | (246 %) | 356 % | (132 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 329 % | 43 % | 39 % | 109 % | - |
Source: Company filings or news article
Related Content
Oncimmune is a pioneering diagnostics company specializing in the early detection of cancer through innovative blood tests. The company primarily serves healthcare providers, patients, and research institutions, operating within the global healthcare and diagnostics market. Oncimmune's core product, the EarlyCDT Lung test, is designed to detect lung cancer at an early stage, improving patient outcomes and survival rates. The business model revolves around the development, marketing, and distribution of these diagnostic tests, generating revenue through sales to hospitals, clinics, and healthcare systems. Oncimmune also collaborates with pharmaceutical companies for biomarker discovery and validation, adding an additional revenue stream. The company's focus on early detection and risk assessment positions it as a key player in the fight against cancer.
Keywords: cancer detection, diagnostics, blood tests, EarlyCDT Lung, healthcare, biomarkers, lung cancer, early detection, risk assessment, biotechnology.
Tech stack
Investments by Oncimmune
Edit